The two doctors attended the EASD diabetes conference in Milan and talk through what surprised them after day one of new GLP-1, obesity and diabetes research.
Recap by typeshit. Video by @drsophiegp on TikTok.
Observational data link GLP-1 drugs to fewer cases of some cancers, but trials have yet to show they prevent cancer or help survival after a diagnosis.
Weight loss may explain much of the knee benefit, but lab work hints at anti-inflammatory and cartilage effects worth a closer read.
She points to work shown at ADA 2026 and published in Nature Communications suggesting semaglutide may improve epigenetic aging markers.
A new GLP-1 described as stronger than current options is being tested in trials, and researchers lay out what people should understand about it.
The NHS says it knows some people are getting hold of retatrutide for weight loss and reminds them the trial drug has no license or approval.
The companies shared aging clock data from semaglutide and tirzepatide trials at a conference. Geneticist Steve Horvath called a two year effect strong.
Loading…